Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 109 to 110 of 110 entries
Sorted by: Best Match Show Resources per page
[No title available]

Molecules (Basel, Switzerland)

Torok R, Horompoly K, Szigeti M, Guttman A, Vitai M, Koranyi L, Jarvas G.
PMID: 34770808
Molecules. 2021 Oct 22;26(21). doi: 10.3390/molecules26216399.

Currently, diagnosing type 2 diabetes (T2D) is a great challenge. Thus, there is a need to find rapid, simple, and reliable analytical methods that can detect the disease at an early stage. The aim of this work was to...

Cite
Torok R, Horompoly K, Szigeti M, et al. . Molecules. 2021;26(21)doi: 10.3390/molecules26216399.
Torok, R., Horompoly, K., Szigeti, M., Guttman, A., Vitai, M., Koranyi, L., & Jarvas, G. (2021). . Molecules (Basel, Switzerland), 26(21), . https://doi.org/10.3390/molecules26216399
Torok, Rebeka, et al. "." Molecules (Basel, Switzerland) vol. 26,21 (2021). doi: https://doi.org/10.3390/molecules26216399
Torok R, Horompoly K, Szigeti M, Guttman A, Vitai M, Koranyi L, Jarvas G. . Molecules. 2021 Oct 22;26(21). doi: 10.3390/molecules26216399. PMID: 34770808; PMCID: PMC8586923.
Copy Download .nbib Format: NLM
N-glycosylation structure - function characterization of omalizumab, an anti-asthma biotherapeutic product.

Journal of pharmaceutical and biomedical analysis

Szabo M, Filep C, Nagy M, Sarkozy D, Szigeti M, Sperling E, Csanky E, Guttman A.
PMID: 34864596
J Pharm Biomed Anal. 2021 Nov 25;209:114483. doi: 10.1016/j.jpba.2021.114483. Epub 2021 Nov 25.

Omalizumab, a glycoprotein based biotherapeutics, is one of the most frequently used targeted antibody biopharmaceutical to reduce asthma exacerbations, improve lung function and reduce oral corticosteroid use. The effector function and clearance time of such glycoprotein drugs is affected...

Cite
Szabo M, Filep C, Nagy M, et al. N-glycosylation structure - function characterization of omalizumab, an anti-asthma biotherapeutic product. J Pharm Biomed Anal. 2021;209:114483doi: 10.1016/j.jpba.2021.114483.
Szabo, M., Filep, C., Nagy, M., Sarkozy, D., Szigeti, M., Sperling, E., Csanky, E., & Guttman, A. (2021). N-glycosylation structure - function characterization of omalizumab, an anti-asthma biotherapeutic product. Journal of pharmaceutical and biomedical analysis, 209114483. https://doi.org/10.1016/j.jpba.2021.114483
Szabo, Miklos, et al. "N-glycosylation structure - function characterization of omalizumab, an anti-asthma biotherapeutic product." Journal of pharmaceutical and biomedical analysis vol. 209 (2021): 114483. doi: https://doi.org/10.1016/j.jpba.2021.114483
Szabo M, Filep C, Nagy M, Sarkozy D, Szigeti M, Sperling E, Csanky E, Guttman A. N-glycosylation structure - function characterization of omalizumab, an anti-asthma biotherapeutic product. J Pharm Biomed Anal. 2021 Nov 25;209:114483. doi: 10.1016/j.jpba.2021.114483. Epub 2021 Nov 25. PMID: 34864596.
Copy Download .nbib Format: NLM
Showing 109 to 110 of 110 entries